Nieiiwe niet-steroïde anti-inflammatoire medicijnen (n s aid 's) met minder bijwerkingen, en vrij verkrijgbare laaggedoseerde preparaten

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 31, 1998, Pages 1757-1761

  Tylgat, G N J ^a  

^a Acadcmisch Modisch Centrum   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NITRIC OXIDE DONOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; AGED; ANIMAL; CAPILLARY; CLASSIFICATION; DIGESTIVE SYSTEM; DRUG EFFECT; DRUG INTERACTION; FEMALE; MALE; MIDDLE AGED; REVIEW; RISK ASSESSMENT;

AGED; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPILLARIES; CYCLOOXYGENASE INHIBITORS; DIGESTIVE SYSTEM; DRUG INTERACTIONS; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; RISK ASSESSMENT;

EID: 0032129168     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hawkey CJ. Karrasch JA, S/c/epanski L. Walker DG. Barkun A. Swanncll AJ. el al. Omepra/ole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998:338:727-34.
2. Yeomans ND. Tulassay Z. Juhâs/ L. Râc/ I. Howard JM. Renshurg CJ van, et al. A comparison of omepra/ole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl ,1 Med 1998:338:719-26.
3. Garcia Rodrigue/ I.A. .lick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994:343:769-72.
4. Schuurman W. Alphen-Jager JM van, Bosch WJHM van den. I.agro HAHM. Willems D, Romeijnders ACM. et al. NHG-standaàrd Reumatoïde artrilis. Huisarts Wet 1994:37:248-59.
5. Gabriel SE. Jaakkimaincn L. Bombardier C. Risk for seriou gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991:115:787-96.
6. Donnelly MT. Hawkey CI. COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997:11:227-36.
7. Hawkey CJ, C'ullen DJE. Greenwood DC. Wilson JV. Logan RFA. Prescribing of nonsteroidal anti-inflammatory drugs in general prac-tice: determinants and consequences. Aliment Pharmacol Ther 1997:11:293-8.
8. Distel M. Mueller C. Bluhmki E. Global analysis of gastrointestinal safety of a new NSA1D. Meloxicam. Inflammopharmacology 1996:4:71-81.
9. Hayllar J. Bjarnason I. NSAIDs. Cox-2 inhibitors, and the gut.Lancet 1995:346:521-2.
10. Laporte JR. Came X. Vidai X. Moreno V. Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and nonsteroidal anti-inflammatory drugs. C'atalan Countries Study on Upper Gastrointestinal Bleeding. Lancet 1991:337:85-9.
11. Henry D. Lim LLY. Garcia Rodriguez LAG. Pere/ Gutthann S. Carson JL. Griffin M. et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996:12: MW».
12. Langman MJS. Weil J. Wainvvright P. Lawson DH. Rawlins MD. Logan RFA. et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994:343: 1075-8.
13. Pairet M. Engelhardt G. Distinct isoforms (C'ox-i and Cox-2) ol'eyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol 1996:10:1-17.
14. Mildiell JA. Akarasereenonl P. Thicmcrmann ('. Flower RJ. Vane JR. Selectivity of nonsleroidal antiinflammatory drugs as inhibitors of constitutive and indueihle cyclooxygenase. Proe Natl Acad Sei L!SA 1993:90:11693-7.
15. Mat-Donald TM. Morant SV. Robinson GC. Shield MJ. McGilchrist MM, Murray FE. et ai. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997:315:1333-7.
16. Flower RJ. New directions in cyclooxygenase research and their implications for NSAID-gastropathy. Ital J (iaslroenterol 1996:28 Suppl 4:23-7.
17. Lipscomb GR. Wallis N. Armstrong (j. Goodman MJ. Rees WDW. Gastric mucosal adaptation to etodolac and naproxen. Alimenl Pharmacol JJier 1995:9:379-85.
18. Reuter BK. Asfaha S.Buret A. Sharkey KA. Wallace JL. Lxaeerbalion of inflammation-associated colonie injur in rat through inhibition of cyclooxyeenase-2. J Clin Invest 1996:98:2076-8.
19. Wallace JL. Gl safe'NSAIDs: are they for real? J Gastroenterol Hepatol 1997:12 SuppkA 144.
20. Wallace JL, Bak A. McKnight W. Asfaha S. Sharkey KA. MacNaughton WK. Cyclooxygenase-1 contributes to inflammatory responses in rats and mice: implications for GI toxicity. Gastroenterology |ter perse].
21. Davies NM. Roseth AG. Apple-yard C13. McKnight W. Del Soldato P. Calignano A. et al. NO-naproxen vs naproxen: uleerogenic. analgesic and anti-inflammatorv effects. Aliment Pharmacol '['her 1997:11:69-79.
22. Somasundaram S. Rail S, Jacob M. Sigthorsson Ci. Mahmud 'L. Sherwood R. et al. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 1997:40:608-13.
23. Wallace JL. Nonsteroidal ami-inllammatory drugs and gastroenteropathy: thé second hundred years. Gastroenterology 1997:112:10006.
24. Koeh M. De/i A, Ferrario F. Capurso I. Prevention of nonsleroidal anti-inflammatory drug-induced gastrointestinal mueosal injury. A meta-analysis of raiidomi/ed controlled clinical trials. Arch Intern Med 1996:156:2321-32.
25. Kelly SM. Jenner JR. Dickinson RJ. Hunter JO. Increased gastiic juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion. Gut 1994:35:611-4.
26. Polk jr WH. Dempsey PJ. Russell WE. Brown PI. Beauchamp RD. Barnard JA. et al. Increased production of transforming growth factor alpha following acute gastric injury. Gastroenterology 1992: 102:1467-74.
27. Nonprescription NSAIDs: efficacy and safeu. Medical Sciences Bulletin 1996.
28. Sarosiek J. Marcinkiewie/ M. Parolisi S. Peura DA. Proslaglandin E2 content in residual gastric juice reflects endoscopie damage to the gastric mueosa after naproxen sodium administration. Am J Gastroenterol 1996:91 73-8.
29. Wilcox CM. Shalek KA. Cotsonis G. Striking prevalence of overthe-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 1994: 154:42-6.
30. DeArmond B. Francisco ÇA. Lin .IS. Huang FY. Halladay S. Bart/iek RD. el al. Safety profile of over-the-counter naproxen sodium. Clin Ther 1995:17:587-601.
31. Whilcomh DC'. Block GD. Association of aeetaminophen hepatotoxieily with fasting and clhanol use. JAMA 1994:272:1X45-50.
32. Makin A.l. Wendon J. Williams R. A 7-year experience of severe aeetaminophen-induced hepalotoxicity (1987-1993). Ciaslroenterology 1995:109:19117-16.
33. Schiodt FV. Rochling FA. Case DL. Lee WM. Aeetaminophen toxieity in an urban county hospital. N EngI J Med 1997:537: [ 112-7.
34. Chan FKL. Sung JJY. Chung SCS. To KF. Yung MY. Leung VKS. et al. Randomised trial of eradication of Helicobactcr pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997:350:975-9.